Published in:
Open Access
01-12-2010 | Research article
The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
Authors:
Guillermo Bastida, Pilar Nos, Mariam Aguas, Belén Beltrán, Marisa Iborra, Vicente Ortiz, Vicente Garrigues, Rafael Estevan, Julio Ponce
Published in:
BMC Gastroenterology
|
Issue 1/2010
Login to get access
Abstract
Background
The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL.
Methods
Ninety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ).
Results
Baseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales.
Conclusions
Thiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients.